Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardioprotection with intravenous statin administration during myocardial infarction vs. oral preloading, a preclinical study

  • Otero, Sergi|||0000-0002-2038-6882
  • Radikė, Monika|||0000-0002-4004-4150
  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Gutiérrez, Manuel
  • Sutelman, Pablo|||0000-0002-4380-0900
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Hidalgo, Alberto
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
Infarct size is associated with all-cause mortality and heart failure hospitalization underscoring the need for effective cardioprotection beyond timely reperfusion.1 Guidelines recommend administering high-potency statins early after ST-elevation myocardial infarction (STEMI) in order to reduce LDL-cholesterol levels as soon as possible.2 However, statins may provide clinical benefits in acute coronary syndrome patients beyond lipid-lowering effects. We have demonstrated in hypercholesterolaemic pigs through cardiac magnetic resonance (CMR) imaging and molecular/histological analyses that intravenous administration of a modified preparation of atorvastatin (i.v.-atorvastatin) during myocardial infarction (MI) limits ischaemia-related cardiac damage3,4 with a legacy effect that attenuates subsequent myocardial injury and preserves cardiac function during reinfarction.5 In addition, we have shown that this i.v.-atorvastatin approach exerts higher cardioprotective effects than those observed when atorvastatin is orally administered early after reperfusion.4 Furthermore, this new cardioprotective strategy is effective in the presence of comorbidities such as diabetic cardiomyopathy.6 However, it remains unknown whether i.v.-atorvastatin during ongoing MI provides superior cardioprotection compared to oral preloading therapy. Here we test this hypothesis in a highly translatable hypercholesterolaemic pig model using CMR.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differentiation of Adipose Tissue Mesenchymal Stem Cells into Endothelial Cells Depends on Fat Depot Conditions, Regulation by miRNA

  • Arderiu, Gemma|||0000-0001-8598-4106
  • Civit-Urgell, Anna|||0000-0002-5804-8408
  • Díez-Caballero, Alberto
  • Moscatiello, Fabrizio
  • Ballesta, Carlos
  • Badimon, Lina|||0000-0002-9162-2459
The development of obesity is associated with substantial modulation of adipose tissue (AT) structure. The plasticity of the AT is reflected by its remarkable ability to expand or reduce in size throughout the adult lifespan, which is linked to the development of its vasculature. This increase in AT vasculature could be mediated by the differentiation of adipose tissue-derived stem cells (ASCs) into endothelial cells (ECs) and form new microvasculature. We have already shown that microRNA (miRNA)-145 regulates the differentiation of ASCs into EC-like (ECL) cells. Here, we investigated whether ASCs-differentiation into ECs is governed by a miRNAs signature that depends on fat depot location and /or the metabolic condition produced by obesity. Human ASCs, which were obtained from white AT by surgical procedures from lean and obese patients, were induced to differentiate into ECL cells. We have identified that miRNA-29b-3p in both subcutaneous (s)ASCs and visceral ASCs and miRNA-424-5p and miRNA-378a-3p in subcutaneous (s)ASCs are involved in differentiation into EC-like cells. These miRNAs modulate their pro-angiogenic effects on ASCs by targeting FGFR1, NRP2, MAPK1, and TGF-β2, and the MAPK signaling pathway. We show for the first time that miRNA-29b-3p upregulation contributes to ASCs' differentiation into ECL cells by directly targeting TGFB2 in both sASCs and visceral ASCs. Moreover, our results reveal that, independent of sASCs' origin (obese/lean), the upregulation of miRNA-378a-3p and the downregulation of miRNA-424-5p inhibit MAPK1 and overexpress FGFR1 and NRP2, respectively. In summary, both the adipose depot location and obesity affect the differentiation of resident ASCs through the expression of specific miRNAs.